Zoë J. Williams

Dr. Zoë J. Williams

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2018 in Skeletal Muscle
Verified
Journal Article
Open access
PDF file
CFCarrie J. Finno
Carrie J. Finno
GGGiuliana Gianino
Giuliana Gianino
SPSudeep Perumbakkam
Sudeep Perumbakkam
ZWZoë J. Williams
Zoë J. Williams
MBMatthew H. Bordbari
Matthew H. Bordbari
SVStephanie J. Valberg
Stephanie J. Valberg
The cause of immune-mediated myositis (IMM), characterized by recurrent, rapid-onset muscle atrophy in Quarter Horses (QH), is unknown. The histopathologic hallmark of IMM is lymphocytic infiltration of myofibers. The purpose of this study was to identify putative functional variants associated with equine IMM. A genome-wide association (GWA) study was performed on 36 IMM QHs and 54 breed matched unaffected QHs from the same environment using the Equine SNP50 and SNP70 genotyping arrays. A mixed model analysis identified nine SNPs within a ~ 2.87 Mb region on chr11 that were significantly (Punadjusted < 1.4 × 10− 6) associated with the IMM phenotype. Associated haplotypes within this region encompassed 38 annotated genes, including four myosin genes (MYH1, MYH2, MYH3, and MYH13). Whole genome sequencing of four IMM and four unaffected QHs identified a single segregating nonsynonymous E321G mutation in MYH1 encoding myosin heavy chain 2X. Genotyping of additional 35 IMM and 22 unaffected QHs confirmed an association (P = 2.9 × 10− 5), and the putative mutation was absent in 175 horses from 21 non-QH breeds. Lymphocytic infiltrates occurred in type 2X myofibers and the proportion of 2X fibers was decreased in the presence of inflammation. Protein modeling and contact/stability analysis identified 14 residues affected by the mutation which significantly decreased stability. We conclude that a mutation in MYH1 is highly associated with susceptibility to the IMM phenotype in QH-related breeds. This is the first report of a mutation in MYH1 and the first link between a skeletal muscle myosin mutation and autoimmune disease.

11 June 2021 in BMC Genomics
Verified
Journal Article
Open access
PDF file
ZWZoë J. Williams
Zoë J. Williams
DVDeborah Velez-Irizarry
Deborah Velez-Irizarry
KGKeri Gardner
Keri Gardner
SVStephanie J. Valberg
Stephanie J. Valberg
Background: Myofibrillar myopathy in humans causes protein aggregation, degeneration, and weakness of skeletal muscle. In horses, myofibrillar myopathy is a late-onset disease of unknown origin characterized by poor performance, atrophy, myofibrillar disarray, and desmin aggregation in skeletal muscle. This study evaluated molecular and ultrastructural signatures of myofibrillar myopathy in Warmblood horses through gluteal muscle tandem-mass-tag quantitative proteomics (5 affected, 4 control), mRNA-sequencing (8 affected, 8 control), amalgamated gene ontology analyses, and immunofluorescent and electron microscopy. Results: We identified 93/1533 proteins and 47/27,690 genes that were significantly differentially expressed. The top significantly differentially expressed protein CSRP3 and three other differentially expressed proteins, including, PDLIM3, SYNPO2, and SYNPOL2, are integrally involved in Z-disc signaling, gene transcription and subsequently sarcomere integrity. Through immunofluorescent staining, both desmin aggregates and CSRP3 were localized to type 2A fibers. The highest differentially expressed gene CHAC1, whose protein product degrades glutathione, is associated with oxidative stress and apoptosis. Amalgamated transcriptomic and proteomic gene ontology analyses identified 3 enriched cellular locations; the sarcomere (Z-disc & I-band), mitochondrial complex I and the extracellular matrix which corresponded to ultrastructural Z-disc disruption and mitochondrial cristae alterations found with electron microscopy. Conclusions: A combined proteomic and transcriptomic analysis highlighted three enriched cellular locations that correspond with MFM ultrastructural pathology in Warmblood horses. Aberrant Z-disc mechano-signaling, impaired Z-disc stability, decreased mitochondrial complex I expression, and a pro-oxidative cellular environment are hypothesized to contribute to the development of myofibrillar myopathy in Warmblood horses. These molecular signatures may provide further insight into diagnostic biomarkers, treatments, and the underlying pathophysiology of MFM.

1 June 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
SVStephanie J. Valberg
Stephanie J. Valberg
DVDeborah Velez-Irizarry
Deborah Velez-Irizarry
ZWZoë J. Williams
Zoë J. Williams
JPJoe D Pagan
Joe D Pagan
VMVanesa Mesquita
Vanesa Mesquita
HMHailey Maresca-Fichter
Hailey Maresca-Fichter
Horses have a slow rate of muscle glycogen repletion relative to other species for unknown reasons. Our aim was to determine the expression of glucose transporters (GLUT) and genes impacting GLUT4 expression and translocation in the gluteal muscle. Five fit Thoroughbred horses performed glycogen-depleting exercises on high-starch (HS, 2869 g starch/day) and low-starch, high-fat diets (LS-HF, 358 g starch/d) with gluteal muscle biopsies obtained before and after depletion and during repletion. Muscle glycogen declined by ≈30% on both diets with little increase during repletion on LS-HF. Transcriptomic analysis identified differential expression (DE) of only 2/12 genes impacting GLUT4 translocation (two subunits of AMP protein kinase) and only at depletion on LS-HF. Only 1/13 genes encoding proteins that promote GLUT4 transcription had increased DE (PPARGC1A at depletion LS-HF). GLUT4 comprised ≈30% of total GLUT mRNA expression at rest. Remarkably, by 72 h of repletion expression of GLUT3, GLUT6 and GLUT10 increased to ≈25% of total GLUT mRNA. Expression of GLUT6 and GLUT10 lagged from 24 h of repletion on HS to 72 h on LS-HF. Lacking an increase in GLUT4 gene expression in response to glycogen-depleting exercise, equine muscle increases GLUT3, GLUT6 and GLUT10 expression potentially to enhance glucose transport, resembling responses observed in resistance trained GLUT4-null mice.

14 September 2022 in Equine Veterinary Journal
Verified
Journal Article
Open access
SVStephanie J. Valberg
Stephanie J. Valberg
ZWZoë J. Williams
Zoë J. Williams
CFCarrie J. Finno
Carrie J. Finno
ASAbigail Schultz
Abigail Schultz
DVDeborah Velez‐Irizarry
Deborah Velez‐Irizarry
JPJessica Lynn Petersen
Jessica Lynn Petersen
Background: Both type 1 (PSSM1) and type 2 polysaccharide storage myopathy (PSSM2) are characterised by aggregates of abnormal polysaccharide in skeletal muscle. Whereas the genetic basis for PSSM1 is known (R309H GYS1), the cause of PSSM2 in Quarter Horses (PSSM2‐QH) is unknown and glycogen concentrations not defined.Objectives: To characterise the histopathological and biochemical features of PSSM2‐QH and determine if an associated monogenic variant exists in genes known to cause glycogenosis.Study design: Retrospective case control.Methods: Sixty‐four PSSM2‐QH, 30 PSSM1‐QH and 185 control‐QH were identified from a biopsy repository and clinical data, histopathology scores (0–3), glycogen concentrations and selected glycolytic enzyme activities compared. Coding sequences of 12 genes associated with muscle glycogenoses were identified from whole genome sequences and compared between seven PSSM2‐QH and five control‐QH.Results: Exertional rhabdomyolysis in PSSM2‐QH occurred predominantly in barrel racing and working cow/roping performance types and improved with regular exercise and a low starch/fat‐supplemented diet. Histopathological scores, including the amount of amylase‐resistant polysaccharide (PSSM2‐QH 1.4 ± 0.6, PSSM1‐QH 2.1 ± 0.3, control‐QH 0 ± 0, p < 0.001), and glycogen concentrations (PSSM2‐QH 129 ± 62, PSSM1‐QH 175 ± 9, control‐QH 80 ± 27 mmol/kg, p < 0.0001) were intermediate in PSSM2‐QH with significant differences among groups. In PSSM2‐QH, abnormal polysaccharide had a less filamentous ultrastructure than PSSM1‐QH and phosphorylase and phosphofructokinase activities were normal. Seventeen of 30 PSSM2‐QH with available pedigrees descended from one of three stallions within four generations. Of the 29 predicted high or moderate impact genetic variants identified in candidate genes, none were present in only PSSM2‐QH and absent in control‐QH.Main limitations: Analyses of PSSM2‐QH and PSSM1‐QH were performed on shipped samples, controls on frozen samples.Conclusions: PSSM2‐QH is a novel glycogen storage disorder that is not the result of a mutation in genes currently known to cause muscle glycogenoses in other species.

5 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZWZoë J. Williams
Zoë J. Williams
MBMegan Bertels
Megan Bertels
SVStephanie J Valberg
Stephanie J Valberg
Type 1 polysaccharide storage myopathy (PSSM1) is a glycogen storage disorder of known cause whereas the basis for type 2 PSSM (PSSM2) is unknown. The same diet and exercise regime prescribed for PSSM1 is recommended for PSSM2; however, the benefit of these recommendations for PSSM2 is undocumented. The objectives of this study were to determine traits of PSSM2 Warmblood horses (WB), determine the changes in exercise responses that occur with a recommended low-starch/fat-supplemented diet and exercise regime, and determine if glycogen concentrations correspond to the severity of signs. Owners of PSSM2 WB (2008–2016), completed a retrospective questionnaire regarding their horse. Glycogen concentrations were analyzed in skeletal muscle of PSSM2 WB (n = 36) obtained prior to recommendations and in control WB with no evident myopathy (n = 23). Chi-square, Fisher’s exact, McNemar’s tests with Bonferroni correction and Mann Whitney testing were utilized. Abnormal exercise responses reported by owners, began at approximately 6 years of age and included a decline in performance, a reluctance to collect and reluctance to go forward in over 50% of horses. With the recommended diet and exercise regime, 80% of PSSM2 WB owners reported an overall improvement with significant decreases in the proportion of horses showing a decline in performance and rhabdomyolysis. However, 53% of PSSM2 WB were still not advancing as expected with reluctance to go forward and collect persisting in approximately one third of horses. Median muscle glycogen concentrations did not differ between PSSM2 WB and WB with no evident myopathy. PSSM2 WB with the highest glycogen concentrations were significantly more likely to show a decline in performance than those with lower glycogen concentrations. In conclusion, diet and exercise recommendations ideal for PSSM1 improve but do not eliminate the decline in performance and reluctance to go forward under saddle characteristic of PSSM2.

25 June 2020 in Equine Veterinary Journal
Verified
Journal Article
Closed access
PDF file
ZWZoë J. Williams
Zoë J. Williams
DVDeborah Velez‐Irizarry
Deborah Velez‐Irizarry
JPJessica L. Petersen
Jessica L. Petersen
JOJulien Ochala
Julien Ochala
CFCarrie J. Finno
Carrie J. Finno
SVStephanie J. Valberg
Stephanie J. Valberg